G1 Therapeutics (GTHX) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

GTHX Stock Forecast

G1 Therapeutics stock forecast is as follows: an average price target of $4.50 (represents a -37.06% downside from GTHX’s last price of $7.15) and a rating consensus of 'Buy', based on 8 wall street analysts offering a 1-year stock forecast.

GTHX Price Target

The average price target for G1 Therapeutics (GTHX) is $4.50 based on 1-year price targets from 8 Wall Street analysts in the past 3 months, with a price target range of $6.00 to $3.00. This represents a potential -37.06% downside from GTHX's last price of $7.15.

GTHX Analyst Ratings

Buy

According to 8 Wall Street analysts, G1 Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for GTHX stock is 0 'Strong Buy' (0.00%), 4 'Buy' (50.00%), 4 'Hold' (50.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

G1 Therapeutics Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Jun 25, 2024	Gil Blum	Needham	$6.00	$2.22	170.27%	-16.08%
Jun 25, 2024	Edward White	H.C. Wainwright	$3.00	$2.22	35.14%	-58.04%

Row per page

Go to

The latest G1 Therapeutics stock forecast, released on Jun 25, 2024 by Gil Blum from Needham, set a price target of $6.00, which represents a 170.27% increase from the stock price at the time of the forecast ($2.22), and a -16.08% decrease from GTHX last price ($7.15).

G1 Therapeutics Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	2
Avg Price Target	-	-	$4.50
Last Closing Price	$7.15	$7.15	$7.15
Upside/Downside	-100.00%	-100.00%	-37.06%

In the current month, the average price target of G1 Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to G1 Therapeutics's last price of $7.15. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Aug 07, 2024	Raymond James	-	Market Perform	Downgrade
Aug 07, 2024	Wedbush	Buy	Neutral	Downgrade
Aug 07, 2024	Needham	Buy	Hold	Downgrade
Aug 07, 2024	Rodman & Renshaw	-	Neutral	Downgrade
Jun 25, 2024	Evercore ISI	-	Outperform	Upgrade
Jun 25, 2024	Wells Fargo	-	Overweight	Upgrade
Jun 25, 2024	H.C. Wainwright	Buy	Buy	Hold
Jun 24, 2024	Cowen & Co.	Buy	Buy	Hold
Jun 13, 2024	Needham	Buy	Buy	Hold
Jun 13, 2024	H.C. Wainwright	Underperform	Underperform	Hold

Row per page

Go to

G1 Therapeutics's last stock rating was published by Raymond James on Aug 07, 2024. The company Downgrade its GTHX rating from "null" to "Market Perform".

G1 Therapeutics Financial Forecast

G1 Therapeutics Revenue Forecast

	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$14.87M	$12.30M	$42.39M	$12.95M	$10.25M	$23.58M	$10.57M	$6.90M	$5.80M	$4.86M	$6.60M	$14.22M	$16.55M	$26.60M
Avg Forecast	$25.50M	$24.43M	$23.33M	$22.23M	$21.09M	$19.94M	$18.79M	$17.65M	$25.71M	$23.81M	$22.07M	$20.43M	$19.54M	$17.96M	$16.26M	$15.21M	$13.08M	$14.24M	$28.95M	$11.17M	$9.66M	$23.33M	$9.14M	$6.37M	$5.71M	$4.78M	$2.77M	$775.00K	$4.64M	$28.57M
High Forecast	$25.50M	$24.43M	$23.33M	$22.23M	$21.09M	$19.94M	$18.79M	$17.65M	$25.71M	$23.81M	$22.07M	$20.43M	$19.54M	$18.63M	$16.26M	$15.21M	$14.60M	$14.24M	$28.95M	$11.17M	$9.66M	$23.33M	$9.14M	$6.37M	$5.71M	$4.78M	$2.77M	$775.00K	$4.64M	$28.57M
Low Forecast	$25.50M	$24.43M	$23.33M	$22.23M	$21.09M	$19.94M	$18.79M	$17.65M	$25.71M	$23.81M	$22.07M	$20.43M	$19.54M	$16.90M	$16.26M	$15.21M	$12.34M	$14.24M	$28.95M	$11.17M	$9.66M	$23.33M	$9.14M	$6.37M	$5.71M	$4.78M	$2.77M	$775.00K	$4.64M	$28.57M
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	2	1	4	5	4	4	4	3	3	3	3	4	4	4	4	5	5
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.14%	0.86%	1.46%	1.16%	1.06%	1.01%	1.16%	1.08%	1.01%	1.02%	2.38%	18.35%	3.56%	0.93%

G1 Therapeutics's average Quarter revenue forecast for Mar 24 based on 4 analysts is $15.21M, with a low forecast of $15.21M, and a high forecast of $15.21M. GTHX's average Quarter revenue forecast represents a 2.27% increase compared to the company's last Quarter revenue of $14.87M (Dec 23).

G1 Therapeutics EBITDA Forecast

	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	2	1	4	5	4	4	4	3	3	3	3	4	4	4	4	5	5
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$-25.20M	$-16.37M	$11.52M	$-24.51M	$-30.04M	$-21.15M	$-36.90M	$-46.81M	$-37.60M	$-41.10M	$-38.16M	$-25.44M	$-23.99M	$-9.84M
Avg Forecast	$-12.61M	$-12.08M	$-11.54M	$-10.99M	$-10.43M	$-9.86M	$-9.29M	$-8.73M	$-12.71M	$-11.78M	$-10.91M	$-10.10M	$-9.66M	$-8.88M	$-8.04M	$-46.13M	$-6.47M	$-7.04M	$-14.32M	$-41.94M	$-44.98M	$-11.54M	$-4.52M	$-38.13M	$-2.83M	$-2.36M	$-1.37M	$-35.42M	$-2.30M	$-14.13M
High Forecast	$-12.61M	$-12.08M	$-11.54M	$-10.99M	$-10.43M	$-9.86M	$-9.29M	$-8.73M	$-12.71M	$-11.78M	$-10.91M	$-10.10M	$-9.66M	$-8.36M	$-8.04M	$-36.91M	$-6.10M	$-7.04M	$-14.32M	$-33.55M	$-35.98M	$-11.54M	$-4.52M	$-30.50M	$-2.83M	$-2.36M	$-1.37M	$-28.34M	$-2.30M	$-14.13M
Low Forecast	$-12.61M	$-12.08M	$-11.54M	$-10.99M	$-10.43M	$-9.86M	$-9.29M	$-8.73M	$-12.71M	$-11.78M	$-10.91M	$-10.10M	$-9.66M	$-9.21M	$-8.04M	$-55.36M	$-7.22M	$-7.04M	$-14.32M	$-50.33M	$-53.97M	$-11.54M	$-4.52M	$-45.75M	$-2.83M	$-2.36M	$-1.37M	$-42.50M	$-2.30M	$-14.13M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3.89%	2.32%	-0.80%	0.58%	0.67%	1.83%	8.17%	1.23%	13.30%	17.38%	27.81%	0.72%	10.45%	0.70%

4 analysts predict GTHX's average Quarter EBITDA for Sep 23 to be $-7.04M, with a high of $-7.04M and a low of $-7.04M. This is -161.15% lower than G1 Therapeutics's previous annual EBITDA (Jun 23) of $11.52M.

G1 Therapeutics Net Income Forecast

	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	2	1	4	5	4	4	4	3	3	3	3	4	4	4	4	5	5
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$-5.94M	$-18.20M	$8.71M	$-32.53M	$-33.65M	$-25.27M	$-41.93M	$-51.60M	$-40.02M	$-42.47M	$-39.42M	$-26.44M	$-25.35M	$-11.67M
Avg Forecast	$5.79M	$5.11M	$4.42M	$3.72M	$2.49M	$1.76M	$1.03M	$325.35K	$5.51M	$3.94M	$2.89M	$-524.75K	$-2.55M	$-4.48M	$-8.66M	$-48.48M	$-14.58M	$-17.88M	$-11.46M	$-44.07M	$-47.87M	$-33.63M	$-53.46M	$-40.06M	$-54.28M	$-53.46M	$-51.21M	$-36.82M	$-47.18M	$-16.00M
High Forecast	$5.79M	$5.11M	$4.42M	$3.72M	$2.49M	$1.76M	$1.03M	$325.35K	$5.51M	$3.94M	$2.89M	$-524.75K	$-2.55M	$-1.87M	$-8.66M	$-38.78M	$-11.88M	$-17.88M	$-11.46M	$-35.26M	$-38.29M	$-33.63M	$-53.46M	$-32.05M	$-54.28M	$-53.46M	$-51.21M	$-29.46M	$-47.18M	$-16.00M
Low Forecast	$5.79M	$5.11M	$4.42M	$3.72M	$2.49M	$1.76M	$1.03M	$325.35K	$5.51M	$3.94M	$2.89M	$-524.75K	$-2.55M	$-6.35M	$-8.66M	$-58.17M	$-15.66M	$-17.88M	$-11.46M	$-52.88M	$-57.44M	$-33.63M	$-53.46M	$-48.08M	$-54.28M	$-53.46M	$-51.21M	$-44.19M	$-47.18M	$-16.00M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.41%	1.02%	-0.76%	0.74%	0.70%	0.75%	0.78%	1.29%	0.74%	0.79%	0.77%	0.72%	0.54%	0.73%

G1 Therapeutics's average Quarter net income forecast for Sep 23 is $-17.88M, with a range of $-17.88M to $-17.88M. GTHX's average Quarter net income forecast represents a -305.23% decrease compared to the company's last Quarter net income of $8.71M (Jun 23).

G1 Therapeutics SG&A Forecast

	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	2	1	4	5	4	4	4	3	3	3	3	4	4	4	4	5	5
SG&A	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$15.17M	$16.78M	$17.43M	$21.75M	$23.56M	$24.43M	$25.72M	$26.71M	$23.22M	$24.27M	$25.24M	$22.97M	$24.26M	$18.41M
Avg Forecast	$42.70M	$40.91M	$39.07M	$37.22M	$35.31M	$33.39M	$31.46M	$29.56M	$43.04M	$39.87M	$36.95M	$34.20M	$32.72M	$30.07M	$27.22M	$25.47M	$21.91M	$23.84M	$48.47M	$18.71M	$16.18M	$39.06M	$15.30M	$10.67M	$9.57M	$8.00M	$4.65M	$1.30M	$7.77M	$47.84M
High Forecast	$42.70M	$40.91M	$39.07M	$37.22M	$35.31M	$33.39M	$31.46M	$29.56M	$43.04M	$39.87M	$36.95M	$34.20M	$32.72M	$31.19M	$27.22M	$25.47M	$24.45M	$23.84M	$48.47M	$18.71M	$16.18M	$39.06M	$15.30M	$10.67M	$9.57M	$8.00M	$4.65M	$1.30M	$7.77M	$47.84M
Low Forecast	$42.70M	$40.91M	$39.07M	$37.22M	$35.31M	$33.39M	$31.46M	$29.56M	$43.04M	$39.87M	$36.95M	$34.20M	$32.72M	$28.29M	$27.22M	$25.47M	$20.66M	$23.84M	$48.47M	$18.71M	$16.18M	$39.06M	$15.30M	$10.67M	$9.57M	$8.00M	$4.65M	$1.30M	$7.77M	$47.84M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.69%	0.70%	0.36%	1.16%	1.46%	0.63%	1.68%	2.50%	2.43%	3.03%	5.43%	17.70%	3.12%	0.38%

G1 Therapeutics's average Quarter SG&A projection for Mar 24 is $25.47M, based on 4 Wall Street analysts, with a range of $25.47M to $25.47M. The forecast indicates a 67.93% rise compared to GTHX last annual SG&A of $15.17M (Dec 23).

G1 Therapeutics EPS Forecast

	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	2	1	4	5	4	4	4	3	3	3	3	4	4	4	4	5	5
EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$-0.00	$-0.00	-	$-0.63	$-0.77	$-0.59	$-0.98	$-1.21	$-0.94	$-1.00	$-0.94	$-0.65	$-0.67	$-0.31
Avg Forecast	$0.11	$0.10	$0.08	$0.07	$0.05	$0.03	$0.02	$0.01	$0.10	$0.07	$0.06	$-0.01	$-0.05	$-0.09	$-0.17	$-0.20	$-0.28	$-0.34	$-0.22	$-0.64	$-0.84	$-0.64	$-1.02	$-0.98	$-1.03	$-1.02	$-0.98	$-1.07	$-0.90	$-0.30
High Forecast	$0.11	$0.10	$0.08	$0.07	$0.05	$0.03	$0.02	$0.01	$0.10	$0.07	$0.06	$-0.01	$-0.05	$-0.04	$-0.17	$-0.20	$-0.23	$-0.34	$-0.22	$-0.64	$-0.84	$-0.64	$-1.02	$-0.98	$-1.03	$-1.02	$-0.98	$-1.07	$-0.90	$-0.30
Low Forecast	$0.11	$0.10	$0.08	$0.07	$0.05	$0.03	$0.02	$0.01	$0.10	$0.07	$0.06	$-0.01	$-0.05	$-0.12	$-0.17	$-0.20	$-0.30	$-0.34	$-0.22	$-0.64	$-0.84	$-0.64	$-1.02	$-0.98	$-1.03	$-1.02	$-0.98	$-1.07	$-0.90	$-0.30
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.00%	0.00%	-0.00%	0.98%	0.91%	0.92%	0.96%	1.23%	0.91%	0.98%	0.96%	0.61%	0.75%	1.02%

According to 4 Wall Street analysts, G1 Therapeutics's projected average Quarter EPS for Sep 23 is $-0.34, with a low estimate of $-0.34 and a high estimate of $-0.34. This represents a -170425.00% decrease compared to GTHX previous annual EPS of - (Jun 23).

G1 Therapeutics Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
FATE	Fate Therapeutics	$2.27	$39.67	1647.58%	Buy
ALLO	Allogene Therapeutics	$2.15	$29.00	1248.84%	Buy
CHRS	Coherus BioSciences	$0.78	$9.00	1053.85%	Hold
XFOR	X4 Pharmaceuticals	$0.37	$3.67	891.89%	Buy
SGMO	Sangamo Therapeutics	$1.90	$12.00	531.58%	Buy
HRTX	Heron Therapeutics	$1.17	$7.00	498.29%	Buy
PDSB	PDS Bio	$2.00	$9.00	350.00%	Buy
SANA	Sana Bio	$2.34	$8.00	241.88%	Buy
LRMR	Larimar Therapeutics	$6.16	$20.33	230.03%	Buy
ABOS	Acumen Pharmaceuticals	$2.24	$7.00	212.50%	Buy
DAWN	Day One Biopharmaceuticals	$13.01	$38.80	198.23%	Buy
MGNX	MacroGenics	$3.51	$10.33	194.30%	Hold
ANNX	Annexon	$5.46	$14.00	156.41%	Buy
RCUS	Arcus Biosciences	$14.43	$33.00	128.69%	Buy
MREO	Mereo BioPharma Group	$3.33	$6.75	102.70%	Buy
CRBU	Caribou Biosciences	$1.98	$3.00	51.52%	Buy
AXSM	Axsome Therapeutics	$92.45	$122.42	32.42%	Buy
AMLX	Amylyx Pharmaceuticals	$5.30	$6.67	25.85%	Buy
BPMC	Blueprint Medicines	$90.18	$109.71	21.66%	Buy
HOOK	HOOKIPA Pharma	$2.80	$3.00	7.14%	Buy
ATRA	Atara Biotherapeutics	$11.33	$10.33	-8.83%	Sell
GTHX	G1 Therapeutics	$7.16	$4.50	-37.15%	Buy

GTHX Forecast FAQ

Is G1 Therapeutics a good buy?

Yes, according to 8 Wall Street analysts, G1 Therapeutics (GTHX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 4 'Buy' recommendations, accounting for 50.00% of GTHX's total ratings.

What is GTHX's price target?

G1 Therapeutics (GTHX) average price target is $4.5 with a range of $3 to $6, implying a -37.06% from its last price of $7.15. The data is based on 8 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will G1 Therapeutics stock go up soon?

According to Wall Street analysts' prediction for GTHX stock, the company can go down by -37.06% (from the last price of $7.15 to the average price target of $4.5), down by -16.08% based on the highest stock price target, and down by -58.04% based on the lowest stock price target.

Can G1 Therapeutics stock reach $11?

GTHX's average twelve months analyst stock price target of $4.5 does not support the claim that G1 Therapeutics can reach $11 in the near future.

What are G1 Therapeutics's analysts' financial forecasts?

G1 Therapeutics's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $77.47M (high $77.47M, low $77.47M), average EBITDA is $-38.315M (high $-38.315M, low $-38.315M), average net income is $5.61M (high $5.61M, low $5.61M), average SG&A $129.72M (high $129.72M, low $129.72M), and average EPS is $0.107 (high $0.107, low $0.107). GTHX's analysts financial forecasts for the fiscal year (Dec 2027) are as follows: average revenue is $95.5M (high $95.5M, low $95.5M), average EBITDA is $-47.23M (high $-47.23M, low $-47.23M), average net income is $19.03M (high $19.03M, low $19.03M), average SG&A $159.9M (high $159.9M, low $159.9M), and average EPS is $0.363 (high $0.363, low $0.363).

Did the GTHX's actual financial results beat the analysts' financial forecasts?

Based on G1 Therapeutics's last annual report (Dec 2023), the company's revenue was $82.51M, beating the average analysts forecast of $67.44M by 22.34%. Apple's EBITDA was $-39.527M, missing the average prediction of $-69.766M by -43.34%. The company's net income was $-47.967M, missing the average estimation of $-87.995M by -45.49%. Apple's SG&A was $71.13M, missing the average forecast of $112.93M by -37.01%. Lastly, the company's EPS was $-0.0009, missing the average prediction of $-1.477 by -99.94%. In terms of the last quarterly report (Dec 2023), G1 Therapeutics's revenue was $14.87M, beating the average analysts' forecast of $13.08M by 13.68%. The company's EBITDA was $-25.195M, beating the average prediction of $-6.471M by 289.37%. G1 Therapeutics's net income was $-5.94M, missing the average estimation of $-14.584M by -59.27%. The company's SG&A was $15.17M, missing the average forecast of $21.91M by -30.77%. Lastly, the company's EPS was $-0.0001, missing the average prediction of $-0.278 by -99.96%